NCT04685135 · OUTCOME

Number of Participants With Maximum CTCAE Grade Laboratory Abnormality in Chemistry Parameters

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation · Source last updated 2026-08-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: From first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks)

What was measured

Blood samples were collected to assess chemistry parameters. Adverse events are graded on a scale from 0 to 4 based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0, with Grade 0 being normal Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.

Analysis population: Safety Population included all the participants who received at least one dose of the study drug. Docetaxel arm do not include adverse events after initiation of crossover Adagrasib treatment.

Groups in this outcome

Adagrasib

Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with Adagrasib tablet or capsule orally at a starting dose of 600 mg twice a day (BID).

Docetaxel

Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with intravenous infusion of Docetaxel at 75 mg/m\^2 over 1 hour or according to institutional practices.

Crossover Adagrasib

Eligible participants receiving Docetaxel earlier in the study switched to Adagrasib based on physician decision. Participants were administered with Adagrasib orally at a starting dose of 600 mg twice a day (BID).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Adagrasib	298
Docetaxel	140
Crossover Adagrasib	44

Reported measurements

Alanine Aminotransferase increased Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	118	Not reported	Not reported	Not reported	Not reported
Docetaxel	118	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	23	Not reported	Not reported	Not reported	Not reported

Alanine Aminotransferase increased Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	107	Not reported	Not reported	Not reported	Not reported
Docetaxel	12	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	11	Not reported	Not reported	Not reported	Not reported

Alanine Aminotransferase increased Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	23	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	4	Not reported	Not reported	Not reported	Not reported

Alanine Aminotransferase increased Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	34	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	1	Not reported	Not reported	Not reported	Not reported

Alanine Aminotransferase increased Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	5	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Alanine Aminotransferase increased Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	11	Not reported	Not reported	Not reported	Not reported
Docetaxel	10	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	5	Not reported	Not reported	Not reported	Not reported

Hypoalbuminemia Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	118	Not reported	Not reported	Not reported	Not reported
Docetaxel	55	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	19	Not reported	Not reported	Not reported	Not reported

Hypoalbuminemia Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	109	Not reported	Not reported	Not reported	Not reported
Docetaxel	51	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	13	Not reported	Not reported	Not reported	Not reported

Hypoalbuminemia Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	58	Not reported	Not reported	Not reported	Not reported
Docetaxel	22	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	7	Not reported	Not reported	Not reported	Not reported

Hypoalbuminemia Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	1	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Hypoalbuminemia Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Hypoalbuminemia Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	12	Not reported	Not reported	Not reported	Not reported
Docetaxel	12	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	5	Not reported	Not reported	Not reported	Not reported

Hypercalcemia Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	260	Not reported	Not reported	Not reported	Not reported
Docetaxel	108	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	35	Not reported	Not reported	Not reported	Not reported

Hypercalcemia Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	24	Not reported	Not reported	Not reported	Not reported
Docetaxel	19	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	3	Not reported	Not reported	Not reported	Not reported

Hypercalcemia Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	1	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Hypercalcemia Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Hypercalcemia Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	1	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Hypercalcemia Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	12	Not reported	Not reported	Not reported	Not reported
Docetaxel	13	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	6	Not reported	Not reported	Not reported	Not reported

Hypocalcemia Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	230	Not reported	Not reported	Not reported	Not reported
Docetaxel	111	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	25	Not reported	Not reported	Not reported	Not reported

Hypocalcemia Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	45	Not reported	Not reported	Not reported	Not reported
Docetaxel	14	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	11	Not reported	Not reported	Not reported	Not reported

Hypocalcemia Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	11	Not reported	Not reported	Not reported	Not reported
Docetaxel	2	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	2	Not reported	Not reported	Not reported	Not reported

Hypocalcemia Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Hypocalcemia Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Hypocalcemia Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	12	Not reported	Not reported	Not reported	Not reported
Docetaxel	13	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	6	Not reported	Not reported	Not reported	Not reported

Alkaline Phosphatase increased Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	165	Not reported	Not reported	Not reported	Not reported
Docetaxel	109	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	24	Not reported	Not reported	Not reported	Not reported

Alkaline Phosphatase increased Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	82	Not reported	Not reported	Not reported	Not reported
Docetaxel	19	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	14	Not reported	Not reported	Not reported	Not reported

Alkaline Phosphatase increased Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	31	Not reported	Not reported	Not reported	Not reported
Docetaxel	2	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	1	Not reported	Not reported	Not reported	Not reported

Alkaline Phosphatase increased Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	8	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Alkaline Phosphatase increased Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	1	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Alkaline Phosphatase increased Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	11	Not reported	Not reported	Not reported	Not reported
Docetaxel	10	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	5	Not reported	Not reported	Not reported	Not reported

Amylase increased Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	181	Not reported	Not reported	Not reported	Not reported
Docetaxel	107	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	31	Not reported	Not reported	Not reported	Not reported

Amylase increased Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	65	Not reported	Not reported	Not reported	Not reported
Docetaxel	11	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	7	Not reported	Not reported	Not reported	Not reported

Amylase increased Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	16	Not reported	Not reported	Not reported	Not reported
Docetaxel	3	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	1	Not reported	Not reported	Not reported	Not reported

Amylase increased Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	6	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Amylase increased Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Amylase increased Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	30	Not reported	Not reported	Not reported	Not reported
Docetaxel	19	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	5	Not reported	Not reported	Not reported	Not reported

Aspartate Aminotransferase increased Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	103	Not reported	Not reported	Not reported	Not reported
Docetaxel	115	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	25	Not reported	Not reported	Not reported	Not reported

Aspartate Aminotransferase increased Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	133	Not reported	Not reported	Not reported	Not reported
Docetaxel	14	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	13	Not reported	Not reported	Not reported	Not reported

Aspartate Aminotransferase increased Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	27	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	1	Not reported	Not reported	Not reported	Not reported

Aspartate Aminotransferase increased Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	20	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Aspartate Aminotransferase increased Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	3	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Aspartate Aminotransferase increased Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	12	Not reported	Not reported	Not reported	Not reported
Docetaxel	11	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	5	Not reported	Not reported	Not reported	Not reported

Bilirubin increased Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	251	Not reported	Not reported	Not reported	Not reported
Docetaxel	125	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	37	Not reported	Not reported	Not reported	Not reported

Bilirubin increased Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	24	Not reported	Not reported	Not reported	Not reported
Docetaxel	2	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	1	Not reported	Not reported	Not reported	Not reported

Bilirubin increased Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	9	Not reported	Not reported	Not reported	Not reported
Docetaxel	1	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	1	Not reported	Not reported	Not reported	Not reported

Bilirubin increased Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	1	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Bilirubin increased Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	2	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Bilirubin increased Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	11	Not reported	Not reported	Not reported	Not reported
Docetaxel	12	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	5	Not reported	Not reported	Not reported	Not reported

Creatinine increased Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	99	Not reported	Not reported	Not reported	Not reported
Docetaxel	99	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	14	Not reported	Not reported	Not reported	Not reported

Creatinine increased Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	55	Not reported	Not reported	Not reported	Not reported
Docetaxel	17	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	9	Not reported	Not reported	Not reported	Not reported

Creatinine increased Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	126	Not reported	Not reported	Not reported	Not reported
Docetaxel	11	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	15	Not reported	Not reported	Not reported	Not reported

Creatinine increased Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	6	Not reported	Not reported	Not reported	Not reported
Docetaxel	3	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	1	Not reported	Not reported	Not reported	Not reported

Creatinine increased Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	1	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Creatinine increased Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	11	Not reported	Not reported	Not reported	Not reported
Docetaxel	10	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	5	Not reported	Not reported	Not reported	Not reported

Fasted Hypoglycemia Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	146	Not reported	Not reported	Not reported	Not reported
Docetaxel	64	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	18	Not reported	Not reported	Not reported	Not reported

Fasted Hypoglycemia Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	15	Not reported	Not reported	Not reported	Not reported
Docetaxel	4	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	2	Not reported	Not reported	Not reported	Not reported

Fasted Hypoglycemia Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	1	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	1	Not reported	Not reported	Not reported	Not reported

Fasted Hypoglycemia Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Fasted Hypoglycemia Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	2	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Fasted Hypoglycemia Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	134	Not reported	Not reported	Not reported	Not reported
Docetaxel	72	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	23	Not reported	Not reported	Not reported	Not reported

Lipase Increased Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	177	Not reported	Not reported	Not reported	Not reported
Docetaxel	109	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	28	Not reported	Not reported	Not reported	Not reported

Lipase Increased Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	63	Not reported	Not reported	Not reported	Not reported
Docetaxel	9	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	7	Not reported	Not reported	Not reported	Not reported

Lipase Increased Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	27	Not reported	Not reported	Not reported	Not reported
Docetaxel	6	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	2	Not reported	Not reported	Not reported	Not reported

Lipase Increased Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	13	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	1	Not reported	Not reported	Not reported	Not reported

Lipase Increased Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Lipase Increased Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	18	Not reported	Not reported	Not reported	Not reported
Docetaxel	16	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	6	Not reported	Not reported	Not reported	Not reported

Hypermagnesemia Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	265	Not reported	Not reported	Not reported	Not reported
Docetaxel	122	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	37	Not reported	Not reported	Not reported	Not reported

Hypermagnesemia Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	19	Not reported	Not reported	Not reported	Not reported
Docetaxel	4	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	2	Not reported	Not reported	Not reported	Not reported

Hypermagnesemia Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Hypermagnesemia Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	1	Not reported	Not reported	Not reported	Not reported
Docetaxel	1	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Hypermagnesemia Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Hypermagnesemia Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	13	Not reported	Not reported	Not reported	Not reported
Docetaxel	13	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	5	Not reported	Not reported	Not reported	Not reported

Hypomagnesemia Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	213	Not reported	Not reported	Not reported	Not reported
Docetaxel	99	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	29	Not reported	Not reported	Not reported	Not reported

Hypomagnesemia Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	67	Not reported	Not reported	Not reported	Not reported
Docetaxel	25	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	10	Not reported	Not reported	Not reported	Not reported

Hypomagnesemia Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	5	Not reported	Not reported	Not reported	Not reported
Docetaxel	3	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Hypomagnesemia Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Hypomagnesemia Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Hypomagnesemia Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	13	Not reported	Not reported	Not reported	Not reported
Docetaxel	13	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	5	Not reported	Not reported	Not reported	Not reported

Non-Fasted Hypoglycemia Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	163	Not reported	Not reported	Not reported	Not reported
Docetaxel	66	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	22	Not reported	Not reported	Not reported	Not reported

Non-Fasted Hypoglycemia Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	9	Not reported	Not reported	Not reported	Not reported
Docetaxel	8	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	3	Not reported	Not reported	Not reported	Not reported

Non-Fasted Hypoglycemia Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	1	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Non-Fasted Hypoglycemia Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Non-Fasted Hypoglycemia Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	3	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Non-Fasted Hypoglycemia Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	122	Not reported	Not reported	Not reported	Not reported
Docetaxel	66	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	19	Not reported	Not reported	Not reported	Not reported

Hyperkalemia Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	206	Not reported	Not reported	Not reported	Not reported
Docetaxel	107	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	28	Not reported	Not reported	Not reported	Not reported

Hyperkalemia Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	54	Not reported	Not reported	Not reported	Not reported
Docetaxel	15	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	8	Not reported	Not reported	Not reported	Not reported

Hyperkalemia Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	20	Not reported	Not reported	Not reported	Not reported
Docetaxel	6	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	3	Not reported	Not reported	Not reported	Not reported

Hyperkalemia Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	5	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Hyperkalemia Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	1	Not reported	Not reported	Not reported	Not reported
Docetaxel	1	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Hyperkalemia Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	12	Not reported	Not reported	Not reported	Not reported
Docetaxel	11	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	5	Not reported	Not reported	Not reported	Not reported

Hypokalemia Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	237	Not reported	Not reported	Not reported	Not reported
Docetaxel	114	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	36	Not reported	Not reported	Not reported	Not reported

Hypokalemia Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	43	Not reported	Not reported	Not reported	Not reported
Docetaxel	11	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	2	Not reported	Not reported	Not reported	Not reported

Hypokalemia Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Hypokalemia Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	6	Not reported	Not reported	Not reported	Not reported
Docetaxel	3	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Hypokalemia Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	0	Not reported	Not reported	Not reported	Not reported
Docetaxel	1	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	1	Not reported	Not reported	Not reported	Not reported

Hypokalemia Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	12	Not reported	Not reported	Not reported	Not reported
Docetaxel	11	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	5	Not reported	Not reported	Not reported	Not reported

Hypernatremia Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	272	Not reported	Not reported	Not reported	Not reported
Docetaxel	130	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	39	Not reported	Not reported	Not reported	Not reported

Hypernatremia Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	14	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Hypernatremia Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Hypernatremia Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	1	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Hypernatremia Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Hypernatremia Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	11	Not reported	Not reported	Not reported	Not reported
Docetaxel	10	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	5	Not reported	Not reported	Not reported	Not reported

Hyponatremia Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	135	Not reported	Not reported	Not reported	Not reported
Docetaxel	95	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	18	Not reported	Not reported	Not reported	Not reported

Hyponatremia Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	126	Not reported	Not reported	Not reported	Not reported
Docetaxel	32	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	19	Not reported	Not reported	Not reported	Not reported

Hyponatremia Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	17	Not reported	Not reported	Not reported	Not reported
Docetaxel	3	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	1	Not reported	Not reported	Not reported	Not reported

Hyponatremia Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	7	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Hyponatremia Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	2	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	1	Not reported	Not reported	Not reported	Not reported

Hyponatremia Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	11	Not reported	Not reported	Not reported	Not reported
Docetaxel	10	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	5	Not reported	Not reported	Not reported	Not reported

Hyperuricemia Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	185	Not reported	Not reported	Not reported	Not reported
Docetaxel	103	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	22	Not reported	Not reported	Not reported	Not reported

Hyperuricemia Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	98	Not reported	Not reported	Not reported	Not reported
Docetaxel	22	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	17	Not reported	Not reported	Not reported	Not reported

Hyperuricemia Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Hyperuricemia Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Hyperuricemia Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Hyperuricemia Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	15	Not reported	Not reported	Not reported	Not reported
Docetaxel	15	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	5	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
118
group Id
OG001
value
118
group Id
OG002
value
23
title
Alanine Aminotransferase increased Grade 0
categories
measurements
group Id
OG000
value
107
group Id
OG001
value
12
group Id
OG002
value
11
title
Alanine Aminotransferase increased Grade 1
categories
measurements
group Id
OG000
value
23
group Id
OG001
value
0
group Id
OG002
value
4
title
Alanine Aminotransferase increased Grade 2
categories
measurements
group Id
OG000
value
34
group Id
OG001
value
0
group Id
OG002
value
1
title
Alanine Aminotransferase increased Grade 3
categories
measurements
group Id
OG000
value
5
group Id
OG001
value
0
group Id
OG002
value
0
title
Alanine Aminotransferase increased Grade 4
categories
measurements
group Id
OG000
value
11
group Id
OG001
value
10
group Id
OG002
value
5
title
Alanine Aminotransferase increased Missing
categories
measurements
group Id
OG000
value
118
group Id
OG001
value
55
group Id
OG002
value
19
title
Hypoalbuminemia Grade 0
categories
measurements
group Id
OG000
value
109
group Id
OG001
value
51
group Id
OG002
value
13
title
Hypoalbuminemia Grade 1
categories
measurements
group Id
OG000
value
58
group Id
OG001
value
22
group Id
OG002
value
7
title
Hypoalbuminemia Grade 2
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
group Id
OG002
value
0
title
Hypoalbuminemia Grade 3
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
title
Hypoalbuminemia Grade 4
categories
measurements
group Id
OG000
value
12
group Id
OG001
value
12
group Id
OG002
value
5
title
Hypoalbuminemia Missing

denoms

counts
group Id
OG000
value
298
group Id
OG001
value
140
group Id
OG002
value
44
units
Participants

description

groups

description
Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with Adagrasib tablet or capsule orally at a starting dose of 600 mg twice a day (BID).
id
OG000
title
Adagrasib
description
Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with intravenous infusion of Docetaxel at 75 mg/m\^2 over 1 hour or according to institutional practices.
id
OG001
title
Docetaxel
description
Eligible participants receiving Docetaxel earlier in the study switched to Adagrasib based on physician decision. Participants were administered with Adagrasib orally at a starting dose of 600 mg twice a day (BID).
id
OG002
title
Crossover Adagrasib

param Type

COUNT_OF_PARTICIPANTS

population Description

Safety Population included all the participants who received at least one dose of the study drug. Docetaxel arm do not include adverse events after initiation of crossover Adagrasib treatment.

reporting Status

POSTED

time Frame

From first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks)

title

Number of Participants With Maximum CTCAE Grade Laboratory Abnormality in Chemistry Parameters

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice